RNS Number : 5664D
OptiBiotix Health PLC
18 November 2026

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Exclusive Distribution deal for SlimBiome in North America

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces that its wholly owned subsidiary, OptiBiotix Limited, has entered into an exclusive distribution agreement (the "Agreement") with CK Ingredients Inc. ("CK") for its appetite-reducing SlimBiome ingredient in North America (Canada and the USA).

CK was incorporated in Ontario, Canada in 1994. It is known in the industry as a trusted supplier of trademarked evidence-backed functional raw materials. It describes itself as a professional sales, marketing and distribution business which identifies and selects unique ingredients that bring value to its clients.

As part of the agreement, CK will acquire OptiBiotix's existing SlimBiome stock held in the USA, arrange import, logistics, and warehousing, manage existing customer accounts (e.g Hydroxycut), assume responsibility for pipeline projects, and invest in promoting SlimBiome to its extensive database of customers throughout Canada and the USA. The Board expects this to reduce operating costs and the need for OptiBiotix to hold its own stock in North America. Exclusivity is linked to annual minimum order quantities (as is common for all OptiBiotix's agreements), failing which the Company has the option to convert the Agreement to non-exclusive.

Stephen O'Hara, CEO of OptiBiotix Health commented: "*We are very pleased to have signed a distribution agreement with CK Ingredients for our award-winning SlimBiome ingredient in the USA and Canada. CK are unique in the industry in that rather than supply a large portfolio of generic ingredients they focus on high value science-based ingredients like SlimBiome which require a more scientific and technical team. We look forward to building our business in the USA with CK.*"

Michael Chenyak, President of CK Ingredients commented: "*The introduction of SlimBiome to our North American customer base could not come at a better time. Interest in the GLP-1 category is burgeoning, and SlimBiome is the perfect science-backed solution for consumers who want to manage their weight and metabolic function safely and naturally. We anticipate very robust demand from North American supplement and functional food brands.*"

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact: OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive

Cairn Financial Advisers LLP (NOMAD and Broker) Tel: 020 7213 0880
Liam Murray / Ludovico Lazzaretti / James Western

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF). OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio of technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGPGCGGUPQGMM